Join Growin Stock Community!

安特羅6564.TW Overview

TW StockBiotech. & Medical
(No presentation for 6564)
My Watchlist

Ticker

Value

empty

There is no following symbol in this watchlist.

安特羅（6564）Overall Performance

安特羅（6564）AI Analysis & Strategy

AI Strategy

Browsing restrictions can be lifted for a fee.

安特羅（6564） PowerScanner

Introduction >>

Power Squeeze

Surfing Trend

1 Day

1 Week

1 Month

安特羅（6564）Key Information

安特羅（6564）Profile

Enimmune corporation operates as a biopharmaceutical Research and development, and marketing company in Taiwan. Its products include Tuberculin PPD RT23 SSI, an approved drug for tuberculin test to determine whether the patient is infected with tuberculosis. The company is also involved in the development of vaccines to prevent various infectious diseases, such as enterovirus, pneumonia, norovirus, dengue fever virus, Middle East respiratory syndrome coronavirus, etc. Enimmune corporation was founded in 2014 and is based in Taichung City, Taiwan.

安特羅（6564）FAQ

This disclaimer is provided by TradingValley Inc. and includes any messages, news, research, analysis, prices or other information provided by the Company's website, the application "Growin App" and other services provided through the Company's website. It is only general market information for educational and investment decision-making reference, and does not constitute any investment advice. View Growin Disclaimer

METRIC
VALUE
vs. INDUSTRY
EPS (TTM)
-5.39
PE Ratio (TTM)
-
Forward PE
-
PS Ratio (TTM)
15.31
PB Ratio
5.85
Price-to-FCF
5.97
METRIC
VALUE
vs. INDUSTRY
Gross Margin
-10.73%
Net Margin
-453.17%
Revenue Growth (YoY)
-71.26%
Profit Growth (YoY)
-115.44%
3-Year Revenue Growth
156.63%
3-Year Profit Growth
151.25%
METRIC
VALUE
vs. INDUSTRY
EPS (TTM)
-5.39
PE Ratio (TTM)
-
Forward PE
-
PS Ratio (TTM)
15.31
PB Ratio
5.85
Price-to-FCF
5.97
Gross Margin
-10.73%
Net Margin
-453.17%
Revenue Growth (YoY)
-71.26%
Profit Growth (YoY)
-115.44%
3-Year Revenue Growth
156.63%
3-Year Profit Growth
151.25%
default symbol

6564

安特羅

18.20D

0.55%

(0.01)

  • When is 6564's latest earnings report released?

    The most recent financial report for 安特羅 (6564) covers the period of 2025Q2 and was published on 2025/06/30. This report is prepared according to IFRS/US GAAP standards and includes key financial indicators—Revenue, Profitability, Cash Flow, and Capital Structure. This information is essential for investors evaluating 6564's short-term business performance and financial health. For the latest updates on 6564's earnings releases, visit this page regularly.

  • How much cash does 6564 have?

    At the end of the period, 安特羅 (6564) held Total Cash and Cash Equivalents of 250.6M, accounting for 0.48 of total assets. Both current and quick ratios indicate robust short-term debt repayment ability. High cash reserves typically mean the company has strong liquidity, supporting operational needs, expansion investments, or shareholder returns.

  • Does 6564 go with three margins increasing?

    In the latest report, 安特羅 (6564) did not achieve the “three margins increasing” benchmark, with a gross margin of 35.57%%, operating margin of -484.55%%, and net margin of -409.32%%. This demonstrates limited improvement in profitability, which is a key signal for fundamental analysis. Investors should consider margin trends alongside other financial indicators to assess 6564's profit trajectory and future growth potential.